GREEN ANDREW M sold $18K of AORT

GREEN ANDREW M (SVP, Regulatory and Quality) sold 616 shares of ARTIVION, INC. (AORT) at $28.55 on 2026-08-14.

Original reporting
SEC EDGAR · GREEN ANDREW M
Published Aug 17, 2026, 7:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 7:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AORT
Neutral
medium confidence
Mentioned
$AORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTNeutralLow
01

Why it matters

The newest disclosed fact is the insider sale details (616 shares, $28.5490/share, total $17,586.18) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale and the lack of a 10b5-1 plan, but there is no accompanying operational or financial catalyst.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing does not indicate intent or future trading.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-17 after-hours/late session; transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction filing for Artivion, Inc. (AORT).

Company-level read

Ticker impact

$AORTNeutralMedium confidence
Context

Artivion disclosed an insider open-market sale by SVP Regulatory and Quality Green Andrew M of 616 shares at $28.5490 on 2026-08-14.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 insider transactions are common and the article provides only sale size and price, with no accompanying company news, guidance, or regulatory/legal event.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a pre-arranged 10b5-1 plan could be interpreted by some traders as less routine, potentially increasing short-term scrutiny.

Key entities

  • ARTIVION, INC.

    Company whose insider transaction was reported on Form 4.

  • GREEN ANDREW M

    SVP, Regulatory and Quality who sold 616 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AORTMedAI 8/10

Artivion Inc (AORT) (Q3 2026) Earnings Call Highlights: Stent Graft Momentum and Nexus

Artivion Inc. reported Q3 2026 earnings, highlighting a gross margin decline to 61.4% due to mix, ramp costs, and charges. CEO Pat Mackin expects a gradual Nexus U.S. launch in 2027. Onyx growth slowed to 13%, with mid-teens full-year growth expected. The company aims to reduce leverage through EBITDA growth, with free cash flow positive in 2027. Core stent graft growth dipped below mid-teens, but is seen as a solid double-digit business.

$AORTHighAI 8/10

Artivion (AORT) Q3 2026 Earnings Call Transcript

Artivion (AORT) reported Q3 2026 revenue of $123.8M, up 9% YoY. Stent graft revenues grew 12%, On-X grew 13%, while tissue processing and BioGlue saw slight declines. Adjusted EBITDA decreased 8% to $22.5M. The company expects U.S. commercial launch of NEXUS in early 2027 and FDA approval for ARCEVO LSA in 2029, unlocking an $80M opportunity. Gross margins fell to 61.4% due to mix and manufacturing investments. Free cash flow was negative $17.6M.

$AORTMed

Artivion: Q3 Earnings Snapshot

Artivion, Inc. (AORT) reported a Q3 loss of $7.9 million, down from a profit last year. Adjusted EPS was 8 cents. Revenue was $123.8 million. The company expects Q4 revenue between $484M and $492M. Shares have fallen 45% YTD and 46% over 12 months.

$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

ARTIVION, INC. (AORT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Artivion Gilmartin Group LLC Lance A. Berry Brian Johnston Executive Vice President, Phone: 332-895-3222 Chief Operating Officer & investors@artivion.com Chief Financial Officer Phone: 770-419-3355 Artivion Reports Third Quarter 2026 F

$AORTMed

Artivion Reports Third Quarter 2026 Financial Results

Artivion reported Q3 2026 revenue of $123.8M, up 9% YoY, with a net loss of $7.9M. Adjusted EBITDA declined 8% to $22.5M. CEO Pat Mackin highlighted growth in On-X and stent grafts, and progress in product launches. The company narrowed its 2026 revenue outlook to $484M-$492M, with adjusted EBITDA expected between $93M-$98M.